A number of research firms have changed their ratings and price targets for Quintiles Transitional Holdings (NYSE: Q):

  • 8/7/2017 – Quintiles Transitional Holdings had its price target raised by analysts at Citigroup Inc. from $96.00 to $97.00. They now have a “neutral” rating on the stock.
  • 8/4/2017 – Quintiles Transitional Holdings was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating. They now have a $93.42 price target on the stock, up previously from $70.10.
  • 8/4/2017 – Quintiles Transitional Holdings was given a new $100.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 8/4/2017 – Quintiles Transitional Holdings had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $94.00 price target on the stock.
  • 8/4/2017 – Quintiles Transitional Holdings had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $92.00 price target on the stock, up previously from $87.00.
  • 8/1/2017 – Quintiles Transitional Holdings was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina. “
  • 7/27/2017 – Quintiles Transitional Holdings was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $101.00 price target on the stock. According to Zacks, “Quintiles Transnational Holdings Inc. provides professional services, information and partnering solutions to the pharmaceutical services, biotechnology and healthcare industries. The Company has two segments: Product Development and Integrated Healthcare Services. It offers project management, clinical monitoring services, strategic planning and design services, consulting services contract sales, market entry/market exit, integrated channel management, patient engagement, market access and commercialization consulting, brand and scientific communication, and medical education services; outcome/observational services. The Company operates in Americas, Europe and Africa, and the Asia-Pacific. Quintiles Transnational Holdings Inc. is based in Durham, North Carolina. “
  • 7/17/2017 – Quintiles Transitional Holdings had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a $98.00 price target on the stock, up previously from $90.00.
  • 7/7/2017 – Quintiles Transitional Holdings was upgraded by analysts at Robert W. Baird from an “underperform” rating to a “neutral” rating. They now have a $93.00 price target on the stock, up previously from $76.00.
  • 6/28/2017 – Quintiles Transitional Holdings had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $96.00 price target on the stock, up previously from $87.00.

Shares of Quintiles Transitional Holdings Inc. (NYSE Q) traded down 2.81% during trading on Thursday, reaching $87.57. 1,364,169 shares of the company were exchanged. The firm has a market cap of $18.96 billion, a price-to-earnings ratio of 253.83 and a beta of 0.64. The stock’s 50-day moving average is $90.13 and its 200-day moving average is $83.39. Quintiles Transitional Holdings Inc. has a 52-week low of $70.10 and a 52-week high of $93.53.

Quintiles Transitional Holdings (NYSE:Q) last posted its quarterly earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.04. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 14.23%. The firm had revenue of $1.97 billion during the quarter, compared to the consensus estimate of $1.96 billion. During the same period in the previous year, the firm posted $0.93 earnings per share. The business’s revenue was up 68.7% compared to the same quarter last year. Equities research analysts predict that Quintiles Transitional Holdings Inc. will post $4.58 earnings per share for the current fiscal year.

In other Quintiles Transitional Holdings news, Director Jack M. Greenberg sold 6,092 shares of Quintiles Transitional Holdings stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $82.50, for a total value of $502,590.00. Following the completion of the sale, the director now directly owns 2,930 shares of the company’s stock, valued at $241,725. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John G. Danhakl sold 761,143 shares of Quintiles Transitional Holdings stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $84.01, for a total transaction of $63,943,623.43. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,850,560 shares of company stock valued at $744,110,641. Insiders own 6.40% of the company’s stock.

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Receive News & Ratings for Quintiles Transitional Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.